53. Sjogren syndrome Clinical trials / Disease details

Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

268 trials found

diseases per page:

Showing 1 to 10 of 268 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05673993 (ClinicalTrials.gov)	April 2023	29/12/2022	A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren' ...	A Phase ?, Multi-center, Randomized, Placebo-controlled, Study to Evaluate the Efficacy and Safety o ...	Primary Sjogren's Syndrome	Biological: Telitacicept 80 mg;Biological: Telitacicept 160 mg;Drug: Placebo	RemeGen Co., Ltd.	NULL	Not yet recruiting	18 Years	70 Years	All	375	Phase 3	China
2	EUCTR2022-001484-27-NL (EUCTR)	24/01/2023	29/10/2022	Basta 2	B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissue ...	Systemic Sclerosis Sjögren's SyndromeCutaneous Lupus Erythematodus;Therapeutic area: Diseases [C] - ...	Product Name: [89Zr]Zr-Df-crefmirlimab berdoxam Product Code: IND 127861 INN or Proposed INN: [89Zr]Zr ...	radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Netherlands
3	EUCTR2021-005911-30-NL (EUCTR)	27/12/2022	24/10/2022	A Study of the safety and effectiveness of Efgartigimod in Patients with Primary Sjögren’s Syndrome ...	A Phase 2, Randomized, Placebo-controlled, Parallel Group, Double-blind, Proof-of-concept Study to E ...	Primary Sjögren’s Syndrome MedDRA version: 21.0;Level: LLT;Classification code 10042846;Term: Syndro ...	Product Name: efgartigimod Product Code: ARGX-113 INN or Proposed INN: Efgartigimod alfa	argenx BV	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Czechia;Hungary;Belgium;Spain;Poland;Germany;Netherlands
4	EUCTR2019-002470-32-NL (EUCTR)	12/12/2022	23/07/2021	NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial b ...	NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial b ...	Primary Sjögren’s syndrome (pSS) MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: S ...	Trade Name: PLAQUENIL Product Name: Hydroxychloroquine INN or Proposed INN: Hydroxychloroquine Other de ...	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 2	Netherlands;Italy
5	NCT05605665 (ClinicalTrials.gov)	November 5, 2022	29/10/2022	Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome	Therapeutic Effect of Low Dose IL-2 Combined With Rapamycin in on sjögren's Syndrome	Sjögren's Syndrome	Drug: low-dose interleukin-2;Drug: rapamycin	Peking University People's Hospital	NULL	Recruiting	18 Years	N/A	All	30	Phase 1/Phase 2	China
6	NCT05383677 (ClinicalTrials.gov)	October 1, 2022	29/3/2022	Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome	ANIfrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome - Efficacy and Safety ...	Sjogren's Syndrome	Drug: Anifrolumab;Drug: Placebo	University Medical Center Groningen	AstraZeneca	Recruiting	18 Years	N/A	All	30	Phase 2	Netherlands
7	JPRN-jRCT1031220298	27/08/2022	27/08/2022	Mucosta trial	A double-blinded, randomised, clinical trial about the effect of rebamipide ophthalmic suspension in ...	Patients with dry eye complicated by Sjogren's syndrome	Each study drug will be administered for a period of 12 weeks from the date of initiation of adminis ...	Shimizu Daisuke	NULL	Recruiting	>= 18age old	Not applicable	Both	40	Phase 4	Japan
8	NCT05349214 (ClinicalTrials.gov)	August 4, 2022	8/4/2022	Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren' ...	A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Effica ...	Sjogren Syndrome	Biological: VAY736;Other: Placebo	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	489	Phase 3	United States;Argentina;Australia;Brazil;Bulgaria;Canada;China;France;Germany;Greece;Hungary;India;I ...
9	EUCTR2021-005687-22-SK (EUCTR)	01/08/2022	12/05/2022	A clinical study to investigate ianalumab is effective and safe in the treatment of active Sjögren`s ...	A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the effica ...	Active Sjögren’s syndrome MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren' ...	Product Name: ianalumab Product Code: VAY736 INN or Proposed INN: IANALUMAB	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	489	Phase 3	United States;Taiwan;Slovakia;Greece;Spain;Lebanon;Israel;Chile;Colombia;Italy;India;France;Australi ...
10	NCT05350072 (ClinicalTrials.gov)	July 28, 2022	7/4/2022	Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's ...	A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Effica ...	Sjogren Syndrome	Biological: VAY736;Other: Placebo	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	285	Phase 3	United States;Austria;Brazil;China;Czechia;France;Germany;Guatemala;Korea, Republic of;Lithuania;Pol ...

First Previous1 2 3 4 5…27Next Last